RT Journal Article
T1 Aggressive and Malignant Prolactinomas.
A1 Olarescu, Nicoleta Cristina
A1 Perez-Rivas, Luis G
A1 Gatto, Federico
A1 Cuny, Thomas
A1 Tichomirowa, Maria A
A1 Tamagno, Gianluca
A1 Gahete, Manuel D
K1 Aggressiveness
K1 Dopamine agonists
K1 Dopamine receptor
K1 Preclinical models
AB Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47-66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumor volume. However, a proportion of prolactinomas exhibit aggressive features (including invasiveness, relevant growth despite adequate dopamine agonist treatment, and recurrence potential) and few may exhibit metastasizing potential (carcinomas). In this context, the clinical, pathological, and molecular definitions of malignant and aggressive prolactinomas remain to be clearly defined, as primary prolactin-secreting carcinomas are similar to aggressive adenomas until the presence of metastases is detected. Indeed, standard molecular and histological analyses do not reflect differences between carcinomas and adenomas at a first glance and have limitations in prediction of the aggressive progression of prolactinomas, wherein the causes underlying the aggressive behavior remain unknown. Herein we present a comprehensive, multidisciplinary review of the most relevant epidemiological, clinical, pathological, genetic, biochemical, and molecular aspects of aggressive and malignant prolactinomas.
PB S. Karger
YR 2019
FD 2019-01-24
LK http://hdl.handle.net/10668/13455
UL http://hdl.handle.net/10668/13455
LA en
NO Olarescu NC, Perez-Rivas LG, Gatto F, Cuny T, Tichomirowa MA, Tamagno G, et al. Aggressive and Malignant Prolactinomas. Neuroendocrinology. 2019;109(1):57-69
NO M.D.G. is supported by and/or hold the following grants: Junta de Andalucía (CTS-1406, BIO-0139); ISCIII-FIS, cofunded by the European Union (ERDF/ESF, Investing in Your Future) (CP15/00156, PI17/02287); and CIBER (an initiative of the Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Socialese Igualdad, Spain). L.G.P.-R. is supported by the Deutsche  Dorschungsgemeinschaft (DFG) within the CRC/Transregio 205/1 (The Adrenal:Central Relay in Health and Disease; Project B17).
DS RISalud
RD Apr 4, 2025